Suggested remit: To appraise the clinical and cost effectiveness of inhaled treprostinil within its marketing authorisation for treating pulmonary hypertension caused by interstitial lung disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6459

Provisional Schedule

Committee meeting 08 October 2025
Expected publication 17 December 2025

Project Team

Project lead Vonda Murray

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 March 2025 Invitation to participate
23 December 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-March 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late May 2025.
12 December 2024 Referral
04 November 2024 - 02 December 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6459
04 November 2024 In progress. Scoping commencing
05 July 2024 Topic selection
02 July 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual